- Previous Close
26.20 - Open
26.01 - Bid 25.89 x --
- Ask 25.90 x --
- Day's Range
25.64 - 26.50 - 52 Week Range
24.40 - 41.49 - Volume
2,819,061 - Avg. Volume
3,233,434 - Market Cap (intraday)
5.221B - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-2.93 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 26, 2023
- 1y Target Est
--
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. The company offers IFA solutions, digital test, oral fluid test, and covid-19 test products; and immunological diagnosis product, such as hair drug test kit, monkeypox, saliva drug test, urine multi-drug test, urine single-drug test, rapid test, digital pregnancy test, male-fertility test, menopause test, and other test products. It also provides molecular diagnosis products, including nucleic acid extraction systems, real time PCR systems, virus detection kits, viral nucleic acid extraction kits, and general products; liquid biochip products; mini immunofluorescence analyzers, handheld fluorescence immunoassay analyzers, fluorescence immunoassay analyzers, handheld oral fluid drug test readers, colloidal gold test readers, and urine drug test cup readers; and dry biochemical strips comprising urine reagent strips, urine analyzers, alcohol test, and vaginal pH test products. In addition, the company offers raw materials for fertility, tumor and cardiac marker, drugs of abuse, infectious diseases, pet, antibody, and others; and FISH probes comprising solid tumor probes, chromosome test, hematologic disease probes, reagents, and instruments. Zhejiang Orient Gene Biotech Co., Ltd was founded in 2005 and is based in Huzhou, China.
www.orientgene.comRecent News: 688298.SS
View MorePerformance Overview: 688298.SS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688298.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688298.SS
View MoreValuation Measures
Market Cap
5.22B
Enterprise Value
2.08B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.27
Price/Book (mrq)
0.76
Enterprise Value/Revenue
2.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-61.88%
Return on Assets (ttm)
--
Return on Equity (ttm)
-7.01%
Revenue (ttm)
826.71M
Net Income Avi to Common (ttm)
-511.6M
Diluted EPS (ttm)
-2.93
Balance Sheet and Cash Flow
Total Cash (mrq)
3.71B
Total Debt/Equity (mrq)
8.00%
Levered Free Cash Flow (ttm)
--